Lexicon Pharmaceuticals Sets Sights on Heart Trial Results, Diabetes Drug Resubmission in 2027

Lexicon Pharmaceuticals (LXRX) expects results from a heart trial and plans to resubmit sotagliflozin for type 1 diabetes in Q1 2027. The company aims for FDA approval in 2027, with safety data from the STENO1 study addressing DKA concerns. Lexicon also plans to market the drug for hypertrophic cardiomyopathy (HCM) separately, with its own pricing and branding.

Original reporting
Published Nov 20, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lexicon Pharmaceuticals Sets Sights on Heart Trial Results, Diabetes Drug Resubmission in 2027 — source image
Decision brief

The 30-second read

$LXRXNeutralMed
01

Why it matters

The disclosed FDA concerns (DKA rates) and the company’s stated alignment on prospective safety criteria, plus STENO1’s reported DKA rate and exposure progress, update the regulatory risk framework for a potential 2027 approval.

02

Market read

Traders can reassess regulatory probability and timeline into 2027 based on the article’s specific FDA-aligned criteria and the reported STENO1 DKA rate progress.

03

What to watch

The article does not quantify the full dataset size beyond the exposure threshold, nor does it detail how FDA will weigh subgroup entry criteria or how the new HCM pricing/product-code strategy could affect near-term cash flows.

Relevance 7/10Novelty 6/10Timing: Q1 2027 resubmission plan, with additional FDA updates during the review and afterward.

Background

Lexicon’s sotagliflozin is already approved for heart failure, and the company is pursuing additional indications including type 1 diabetes via a planned FDA resubmission under a new name (ZYNQUISTA).

Company-level read

Ticker impact

$LXRXNeutralMedium confidence
Context

Lexicon plans to resubmit sotagliflozin (ZYNQUISTA) for type 1 diabetes in Q1 2027 after FDA concerns on DKA, using STENO1 safety data.

Expected impact

Likely modest upside bias if traders view the STENO1 DKA rate and exposure threshold as de-risking the resubmission, but volatility remains tied to FDA review outcomes.

Evidence & confidence

The article provides specific FDA-aligned criteria (patient-years exposure threshold and DKA rate target) and states STENO1 has reached exposure and recorded a DKA rate near the untreated control, which can improve perceived regulatory odds ahead of the 2027 decision window.

Market effects

Reinforces the importance of prospective DKA safety datasets for SGLT2-class drugs in type 1 diabetes, potentially affecting sentiment around similar programs.

Limited direct regional impact; primarily US biotech regulatory and clinical-trial sentiment.

Moderate global relevance for diabetes drug development, but the catalyst is US FDA review timing.

Counterpoint

Even with STENO1 meeting exposure and showing a low DKA rate, FDA may still require additional prospective evidence or interpret endpoints more conservatively, delaying or limiting approval odds.

Key entities

  • Lexicon Pharmaceuticals

    NASDAQ-listed biopharma planning a Q1 2027 FDA resubmission for type 1 diabetes using STENO1 safety data.

  • sotagliflozin (ZYNQUISTA)

    SGLT2 inhibitor being resubmitted for type 1 diabetes; FDA concerns center on diabetic ketoacidosis rates.

  • STENO1

    Third-party open-label study providing prospective safety data for the resubmission.

  • FDA

    Raised concerns about DKA rates and requested new prospective safety data for the resubmission.

Related articles

$LXRXMed

What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call

Lexicon Pharmaceuticals (LXRX) reported Q3 earnings, delaying ZYNQUISTA's diabetes application resubmission to Q1 2027 due to data preparation. The company presented preclinical obesity findings for pilavapadin and received a $10M milestone payment from Novo Nordisk. R&D expenses fell to $16.2M, while cash reserves stood at $183.2M.

$LXRXMed

Lexicon Pharmaceuticals Inc (LXRX) (Q3 2026) Earnings Call Highlights: Sonata HCM Data

Lexicon Pharmaceuticals (LXRX) reported Q3 2026 revenues of $11.3M, including a $10M milestone from Novo Nordisk. Key updates: Phase 3 Sonata HCM trial data expected Q1 2027, LX-9851 program advancing, and positive preclinical obesity data for pilavapidin. Net loss was $14.0M, or $0.03 per share, with $183.2M in cash. The company highlighted upcoming milestones, including the Sonata HCM data readout and Zynquista NDA resubmission in Q1 2027.

$LXRXMed

Lexicon (LXRX) Q3 2026 Earnings Call Transcript

Lexicon (LXRX) reported Q3 2026 progress, including completion of patient enrollment in the phase III SONATA-HCM study for HCM, with top-line results expected in Q1 2027. The company also made strides in resubmitting the NDA for ZYNQUISTA in type 1 diabetes, supported by new safety data from the STENO1 study, aiming for resubmission in Q1 2027.

$LXRXMed

LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled…

LEXICON PHARMACEUTICALS, INC. (LXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resu

$LXRXMedAI 8/10

Lexicon shares baseline data from heart disease drug trial

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported baseline data from its Phase 3 SONATA-HCM trial for sotagliflozin, enrolling 542 patients with hypertrophic cardiomyopathy. The study aims to measure symptom improvement using the KCCQ-CSS score, with topline results expected in Q1 2027. The trial includes patients with non-obstructive and obstructive HCM, with no FDA-approved treatments currently available for the former.